Investor Relations :: SCYNEXIS, Inc. (SCYX)

Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

First Name

Last Name

Email Address

Contact Type:

Sign me up for:

Press Releases

Annual & Quarterly Reports

Current Reports

Insider Transactions

Proxy Information

All Filings

SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Dec 1, 2022

View All News

Q3 2022

Quarter Ended Sep 30, 2022

PDF HTML

Earnings Release

Audio

Earnings Webcast

PDF HTML

10-Q

ZIP XLS HTML

XBRL

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

Investor Presentation

Download

Symbol

Nasdaq: SCYX

Price

Change

Daily Volume

52-week Low/High

Day Low/High

Investor Contact Information